86 participants
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2014-12-24
- Start Date:
- 2014-07-31
- Completion:
- 2015-12-31
Conditions
- Self Efficacy
- Adverse Drug Event
- Carcinoma, Renal Cell
Interventions
- DRUG
No Results Yet